OAC
CTMX icon

OMERS Administration Corp’s CytomX Therapeutics CTMX Stock Holding History

OMERS Administration Corp’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,400
Closed -$293K – 972
2026
Q1 		$293K Sell
62,400
-25,400
-29% -$129K ﹤0.01% 859
2025
Q4 		$374K Buy
+87,800
New +$334K ﹤0.01% 760
2024
Q2 		– Sell
-35,400
Closed -$77.2K – 1086
2024
Q1 		$77.2K Buy
+35,400
New +$65.3K ﹤0.01% 348

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

OMERS Administration Corp's CTMX Position: Q2 2026 in Review

OMERS Administration Corp sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 62,400 shares — an estimated $293K sold.

OMERS Administration Corp first reported a position in CTMX in Q1 2024 and held it in 3 quarters. The position peaked at $374K in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • OMERS Administration Corp reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 62,400 CytomX Therapeutics shares in Q2 2026, an estimated $293K.
  • OMERS Administration Corp first reported a position in CytomX Therapeutics in Q1 2024 and held it in 3 quarters.
  • OMERS Administration Corp's CytomX Therapeutics position peaked at $374K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.